title: Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics.
abstract: Chronic kidney disease (CKD) is recognized to cause pharmacokinetic changes in renally excreted drugs; however, pharmacokinetic changes are also reported for drugs that are nonrenally eliminated. Few studies have investigated how uremic toxins may affect drug transporters and metabolizing enzymes and how these may result in pharmacokinetic/metabolic changes in CKD. Here, we investigated the effects of uremic toxins and human uremic serum on the transport of the prototypical transporter substrate [(3) H]-estrone sulfate and three Biopharmaceutics Drug Disposition Classification System (BDDCS) drugs, propranolol, losartan, and eprosartan. We observed a significant decrease in [(3) H]-estrone sulfate, losartan, and eprosartan uptake with some uremic toxins in both transfected cells and rat hepatocytes. The uptake of losartan was decreased in rat and human hepatocytes (28% and 48%, respectively) in the presence of hemodialysis (HD) serum. Time-course studies of losartan showed a 27%, 65%, and 68% increase in area under the curve (AUC) in the presence of HD serum, rifampin, and sulfaphenazole, respectively. Intracellular losartan AUC decreased significantly in the treatment groups, and the metabolite AUC decreased by 41% and 26% in rifampin- and sulfaphenazole-treated group, respectively. The intracellular AUC of eprosartan increased 190% in the presence of HD serum. These studies indicate that the uremic toxins contained in HD serum play an important role in drug disposition through drug transporters, and that there would be differential effects depending on the BDDCS classification of the drug.
authors: Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California 94143-0912, USA.
authors: Maribel
authors: M
authors: Reyes
authors: Leslie Z
authors: LZ
authors: Benet
references: Int J Clin Pharmacol Ther. 2009 Jan;47(1):61-4
references: 19203541
references: Br J Pharmacol. 2005 Apr;144(8):1067-77
references: 15700027
references: Clin Pharmacol Ther. 2009 Jan;85(1):78-85
references: 18843263
references: Clin Pharmacol Ther. 2008 Jun;83(6):898-903
references: 18388866
references: Pharm Res. 2009 Sep;26(9):2039-54
references: 19568696
references: Drug Metab Dispos. 2004 Nov;32(11):1239-46
references: 15286055
references: J Clin Pharm Ther. 2009 Oct;34(5):585-94
references: 19744014
references: Drug Metab Dispos. 2006 Apr;34(4):702-8
references: 16443666
references: Semin Dial. 2003 Jan-Feb;16(1):45-50
references: 12535300
references: Drug Metab Dispos. 2006 Aug;34(8):1336-44
references: 16698890
references: Kidney Int. 2003 May;63(5):1934-43
references: 12675874
references: J Am Soc Nephrol. 2009 Oct;20(10):2269-76
references: 19696225
references: J Pharmacol Exp Ther. 2006 Feb;316(2):762-71
references: 16258024
references: Eur J Clin Pharmacol. 1992;42(6):671-3
references: 1623911
references: Clin Pharmacol Ther. 2009 Mar;85(3):305-11
references: 19020495
references: J Am Soc Nephrol. 2001 Feb;12(2):326-332
references: 11158222
references: Curr Opin Nephrol Hypertens. 2008 Nov;17(6):555-9
references: 18941346
references: Pharmacogenet Genomics. 2008 Jul;18(7):559-68
references: 18551036
references: Hepatology. 2009 Oct;50(4):1014-6
references: 19787812
references: J Pharmacol Exp Ther. 2004 Mar;308(3):1040-5
references: 14634033
references: J Pharmacol Sci. 2008 Oct;108(2):157-63
references: 18845914
references: Expert Opin Drug Metab Toxicol. 2005 Oct;1(3):429-45
references: 16863454
references: Xenobiotica. 1999 Feb;29(2):171-85
references: 10199593
references: Pharm Res. 1996 Apr;13(4):497-513
references: 8710738
references: Drug Metab Dispos. 2009 Feb;37(2):386-90
references: 19022942
references: Ther Drug Monit. 2008 Oct;30(5):576-82
references: 18708994
references: Clin Pharmacol Ther. 2010 Apr;87(4):465-72
references: 20090676
references: J Clin Pharmacol. 1998 Feb;38(2):129-37
references: 9549643
references: Pharm Res. 2005 Jan;22(1):11-23
references: 15771225
references: Drug Metab Pharmacokinet. 2003;18(1):33-41
references: 15618717
references: Br J Pharmacol. 2002 Dec;137(7):1039-46
references: 12429576
references: Curr Drug Metab. 2003 Apr;4(2):91-103
references: 12678690
references: Pharm Res. 2007 Feb;24(2):239-47
references: 17177112
references: Kidney Int. 2002 May;61(5):1760-8
references: 11967025